Han HJ, Lim MJ, Lee YJ, Lee JH, Yang IS, Taub M. Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-B.
3
H]thymidine incorporation caused by uric acid can be explained by two distinct mechanisms, the activation of NF-B as well as the activation of PLA 2. kidney; hyperuricemia HYPERURICEMIA HAS BEEN IMPLICATED in the development of diverse renal diseases, including the formation of urinary stones (29, 35) . Not only is uric acid a frequent component of urinary stones, but in addition it can be a contributing factor in the formation of calcium oxalate stones themselves (17) . Uric acid is the end product of purine metabolism in humans, which, unlike other mammals, are deficient in the enzyme uricase (42) . Uric acid is freely filtered by the glomerulus and is reabsorbed in the early renal proximal convoluted tubule via a uric acid transporter followed by secretion possibly in the S2 segment, and finally postsecretory reabsorption (12, 16) . Hyperuricemia may occur because of an overall decrease in secretion, an increase in uric acid production (resulting in an increase in the serum uric acid level), or both (14) . Although generally uric acid has been considered inert, there is evidence that soluble uric acid can induce vascular smooth muscle cells to proliferate in vitro (28, 38) . Di Giovine et al. (8) also reported that uric acid stimulates the growth of T cells and synovial fibroblasts. However, uric acid inhibits the growth of pulmonary smooth muscle cells, without causing cell injury (21) .
In vivo, hyperuricemia ultimately may result in renal disease. Included among the deleterious effects of hyperuricemia is interstitial renal disease, as well as tubular injury (34) . Hyperurecimia may be induced during treatment with such drugs as diuretics (16) . In addition ethanol and salicylates may result in a decrease in the tubular secretion of uric acid (16) . Uric acid is also a contributing factor in the pathogenesis of essential hypertension (13) . Clinical investigations have revealed that the hyperuricemia that occurs following renal transplantation is primarily related to a reduction in the tubular secretion of uric acid (23) . These reports suggest that uric acid is retained in renal proximal tubule epithelial cells (PTCs), causing renal tubular dysfunction, which is caused, in part, by alterations affecting the proliferation of renal PTCs. The mechanisms by which uric acid affects renal PTC growth may be similar to the reported effects of uric acid on such cell types as vascular smooth muscle cells, where p44/42 and p38 MAPK are activated in addition to the activation of cyclooxygenase-2 and the transcription factor nuclear factor-B (NF-B) (27) . Similarly, monosodium urate monohydrate reportedly activates p38 MAPK in chondrocytes (32) . Uric acid may affect the function of renal PTCs via a similar spectrum of diverse signaling pathways. However, the mechanisms underlying the affects of uric acid on the proliferation of renal PTCs have not previously been elucidated.
A convenient means for defining the effects of uric acid on renal proximal tubule epithelial cells is through in vitro studies with differentiated cells in culture. The primary rabbit renal PTC culture system utilized in this study retains in vitro the differentiated phenotype typical of the cells in the renal proximal tubule, including a polarized morphology (7, 41, 45) , as well as distinctive renal proximal tubule transport systems, and hormone responses (18, 19) . The present study was performed to identify specific intracellular signaling pathways that are targeted by uric acid in particular under conditions of hyperuricemia and are responsible for the effects of uric acid on renal PTC growth. We present evidence indicating, first, that uric acid inhibits DNA synthesis by the PTCs, and second, that the inhibitory effect of uric acid on DNA synthesis is mediated by at least two distinct signaling pathways, one that involves the activation of NF-B and another that involves the activation of cPLA 2 , which occurs via the initial activation of PKC, and subsequent activation of p38 MAPK.
MATERIALS AND METHODS
Materials. Adult New Zealand White male rabbits (1.5-2.0 kg) were from Dae Han Experimental Animal Co., (Chungju, Korea). All procedures for animal management followed the standard operation protocols of Chonnam National University. An Institutional Review Board at Chonnam National University approved our research proposal and relevant experimental procedures, including animal care. Appropriate management of experimental samples and quality control of the laboratory facility and equipment were maintained. Class IV collagenase and soybean trypsin inhibitor were from Life Technologies (Grand Island, NY). Uric acid, mepacrine, arachidonyl trifluoromethyl ketone (AACOCF 3), SP 600125, and SB 203580 were from Sigma (St. Louis, MO). PD 98059, pyrrolidine dithiocarbamate (PDTC), and SN 50 were from Calbiochem (La Jolla, CA). [ 3 H]thymidine and [␥-
32 P]ATP were from DuPont/NEN (Boston, MA), and Liquiscint was from National Diagnostics (Parsippany, NJ). Antibody to p44/42, p38, SAPK/JNK, PKC, cPLA 2, and IB-␣ were from Santa Cruz Biotechnology (Santa Cruz, CA). All other reagents were of the highest purity commercially available.
Isolation of rabbit renal proximal tubules and culture conditions. Primary rabbit kidney proximal tubule cell cultures were prepared by a modification of the method of Chung et al. (7) . Kidneys were perfused via the renal artery, first with PBS, and then with DMEM/ F-12 containing 0.5% iron oxide (wt/vol) until the kidney turned gray-black. Renal cortical slices were disrupted (4 strokes; Dounce homogenizer), and the homogenate was passed sequentially through a 253-m filter and an 83-m mesh filter. The tubules and glomeruli on the top of the 83-m filter were transferred into sterile DMEM/F-12, and glomeruli containing iron oxide were removed using a magnetic stirring bar. The remaining proximal tubules were briefly incubated in DMEM/F-12 containing 60 g/ml collagenase (class IV) and 0.025% soybean trypsin inhibitor, washed by centrifugation, and resuspended in DMEM/F-12 containing three growth supplements (5 g/ml insulin, 5 g/ml transferrin, and 5 ϫ 10 Ϫ8 M hydrocortisone). After plating, the PTCs were maintained at 37°C in a 5% CO2 humidified environment in DMEM/F-12 medium containing the three supplements. The medium was changed 1 day after plating and then every 3 days. PTC cultures possess a number of characteristics typical of proximal tubules, including Na ϩ -dependent ␣-methylglucoside uptake, PTH-sensitive cAMP synthesis, and the brush-border enzymes leucine amino peptidase, r-glutamyl transpeptidase, and alkaline phosphatase. These characteristics differ from those of primary cell cultures derived from unpurified rabbit kidney preparations.
[ 3 H]thymidine incorporation. The rate of DNA synthesis was determined by [ 3 H]thymidine incorporation studies (6) . To summarize, PTCs were incubated in either the presence or absence of uric acid for 24 h, followed by a 24-h incubation with 1 Ci of [methyl-3 H]thymidine (37°C). The cultures were washed with PBS, fixed (10% trichloroacetic acid, 23°C, 15 min), and then washed twice (5% TCA). The TCA-precipitable material was solubilized (2 N NaOH, 23°C), and the radioactivity was counted in a liquid scintillation counter (LS 6500, Beckman Instruments, Fullerton, CA), using Liquiscint scintillation fluid. All experiments were performed in triplicate, and values were compared percentagewise to the control (mean counts/min in the presence of uric acid divided by mean counts/min in the absence of uric acid and multiplied by 100).
Cell viability and LDH assay. The number of cells and viability were counted using the following methodology. The cells were washed twice with PBS and trypsinized from the culture dishes; then, the cell suspension was mixed with a 0.4% (wt/vol) trypan blue solution and the number of live cells was determined using a hemocytometer. Cells failing to exclude the dye were considered nonviable. Cell injury was assessed by LDH activity. The level of LDH activity in the medium was measured by using a LDH assay kit. For measurement of LDH activity, PTCs were treated with different concentration of uric acid for 8 h. LDH activity was expressed as the percentage of control.
Arachidonic acid release. To quantitate arachidonic acid (AA) release by modification of the method of Xing et al. (44) , confluent PTCs were incubated for 24 h (DMEM/F-12ϩ0.5 Ci/ml [ 3 H]AA and the 3 growth supplements). The monolayers were then washed and incubated for 1 h (37°C; DMEM/F-12 with specified factors). At the end of the incubation, the medium was transferred to ice-cold tubes containing 55 mM EGTA and 5 mM EDTA, centrifuged (12, Membrane preparation for cPLA 2 and PKC blotting. The day before the experiment, the medium was changed and after appropriate treatments, the medium was removed. The cells were washed in PBS and removed by scraping into PBS. After microcentrifugation, the cells were resuspended in buffer A (in mM: 137 NaCl, 8.1 Na 2HPO4, 2.7 KCl, 1.5 KH2PO4, 2.5 EDTA, 1 dithiothreitol, and 0.1 PMSF, as well as 10 g/ml leupeptin, pH 7.5) and lysed by trituration with a 21.1-gauge needle. The lysates were first centrifuged (1,000 g, 10 min, 4°C), followed by centrifugation (100,000 g, 1 h, 4°C). The particulate fractions were suspended in buffer A, washed by centrifugation, and finally resuspended in buffer A containing 0.05% (vol/vol) Triton X-100. The protein content of each fraction was quantified by the Bradford procedure (5).
Western blot analysis. PTCs were solubilized in sample buffer (10% SDS, 20% glycerol, 2% ␤-mercaptoethanol, 2.9 mM Tris, pH 6.8). Samples (20 g) subjected to electrophoresis through 10% SDS-polyacrylamide gels were transferred to nitrocellulose. The nitrocellulose blots were blocked with 5% skim milk in TBST (10 mM Tris ⅐ HCl, pH 7.6, 150 mM NaCl, 0.05% Tween 20) for 1 h and incubated with primary antibody at dilutions recommended by the supplier. The blots were then washed and then incubated with goat anti-rabbit-IgG conjugated to horseradish peroxidase. The bands were visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech).
EMSA. EMSAs were performed as previously described by Jeon et al. (25) with modification. PTCs were lysed in hypotonic buffer (10 mM HEPES, 1.5 mM MgCl 2, 1% Nonidet P-40, pH 7.5) and centrifuged (3,000 g, 5 min). The nuclear pellet was solubilized in hypertonic buffer (in mM: 30 HEPES, 1.5 MgCl 2, 450 KCl, 0.3 EDTA, 1 DTT, and 1 PMSF, as well as 10% glycerol, 1 g/ml of aprotinin, and 1 g/ml of leupeptin), and, after lysis, was centrifuged (14,500 g, 15 min). DNA binding assays were then conducted (36) by incubating nuclear extracts (5 g) with poly (dI-dC) and a [␥-
32 P]-labeled DNA probe (5Ј-GAT-CTC-AGA-GGG-GAC-TTT-CCG-AGA-GA-3Ј) in binding buffer (in mM: 100 KCl, 30 HEPES, 1.5 MgCl 2, 0.3 EDTA, 1 DTT, and 1 PMSF, as well as 10% glycerol, 1 g/ml of aprotinin, and 1 g/ml of leupeptin) for 10 min. Nuclear protein/DNA complexes were separated from free probe by electrophoresis through a 4.8% polyacrylamide gel in ϫ0.5 TBE buffer. Following electrophoresis, the gel was dried and subjected to autoradiography.
Statistical analysis. Results were expressed as means Ϯ SE. The difference between two mean values was analyzed by means of ANOVA. Differences were considered statistically significant when P Ͻ 0.05. by means of [ 3 H]thymidine incorporation studies. The effect of uric acid on [ 3 H]thymidine incorporation was initially determined at a uric acid concentration characteristic of individuals with hyperuricemia (500 M) (16) . When the effect of 500 M uric acid was examined as a function of time (0 -24 h), a significant inhibition in [ 3 H]thymidine incorporation was observed after a 2-h incubation (Fig. 1A) . The inhibition increased to 37 Ϯ 4% of the control at the end of the 24-h incubation period. The effect of uric acid on [ 3 H]thymidine incorporation was also determined as a function of uric acid concentration (0 -10 Ϫ3 M). Figure 1B shows that when uric acid was present within a physiological concentration range for the rabbit (ϳ20 M) no significant inhibition was observed. However, when the uric acid level was increased above 50 M [ 3 H]thymidine incorporation was significantly reduced (20% inhibition at 10 Ϫ4 M, and up to 70% inhibition at 10 Ϫ3 M), although there is no cytotoxic effect within these concentration ranges (Table 1 ). In humans, normal uric acid levels are higher than in the rabbit (up to 350 M), and hyperuricemia is observed at uric acid levels Ͼ420 M. For this reason, all subsequent experiments were performed using 5 ϫ10 Ϫ4 M uric acid for 8 h.
Involvement of PKC and MAPKs in the uric acid-induced inhibition of [
3 H]thymidine incorporation. Previously, PKC was proposed as being a possible mediator of the effects of uric acid on vascular smooth muscle cell proliferation (38) . For this reason, the involvement of PKC as a mediator of the inhibitory effect of uric acid on [ 3 H]thymidine incorporation was examined. Three different PKC inhibitors, bisindolylmaleimide I (10 Ϫ7 M), staurosporine (10 Ϫ9 M), and H-7 (10 Ϫ7 M), were employed. Figure 2A shows that each of the three PKC inhibitors individually blocked the uric acid-induced inhibition of [ 3 H]thymidine incorporation. This result suggests that PKC activation is required for the effect of uric acid on [
3 H]thymidine incorporation to be elicited. Indeed, Fig. 2B shows evidence of the translocation of PKC from the cytosol to the particulate fraction following treatment with uric acid.
Previously, uric acid was observed to activate MAPK in vascular smooth muscle cells, an event that was associated with the stimulatory effect of uric acid on vascular smooth muscle cell growth (30) . Thus the possibility was evaluated that MAPKs are similarly involved in mediating the uric acid-induced inhibition of [ 3 H]thymidine incorporation in PTCs. Figure 3A shows the effect of uric acid on the activation of p38 MAPK, SAPK/JNK, and p44/42 MAPK over a 4-h incubation period. In uric acid-treated cultures, the level of phosphorylation of p38 MAPK and SAPK/JNK increased ϳ3.5-fold between a 10-and 15-min incubation period and then decreased to the control level (the level observed at time 0). As observed with p38 MAPK, p44/42 MAPK phosphorylation also increased transiently, starting from 10 min, but returning to control levels following a 4-h incubation with uric acid (Fig. 3A) . Possibly, the activation of either p38 MAPK, SAPK/JNK, or p44/42 MAPK is required to observe the uric acid-mediated inhibition of 
acid-induced inhibition of [
3 H]thymidine incorporation was examined. The possible involvement of cPLA 2 was also examined. Figure 4 shows that the uric acid-induced activation of p38 MAPK was blocked by H-7 (a PKC inhibitor, 10 Ϫ7 M) as well as by SB 203580 (a p38 MAPK inhibitor, 10 Ϫ7 M), but not by AACOCF 3 (a cPLA 2 inhibitor, 10 Ϫ6 M). These observations are consistent with the hypothesis that MAPK activation that occurs in response to uric acid is dependent on the activation of PKC, rather than cPLA 2 .
However, these latter observations do not exclude the hypothesis that PLA 2 activation is a part of the response of PTCs to elevated uric acid. To evaluate whether PLA 2 is involved in the uric acid response, the effect of uric acid on [ 3 H]AA release was examined. Figure 5A shows that [ 3 H]AA release increased significantly after a 1-h incubation with uric acid at a concentration of 10 Ϫ4 M. Also consistent with the involvement of PLA 2 were our observations indicating that following uric acid treatment, cPLA 2 translocated from the cytosol to the particulate fraction (Fig. 5B) . The observation (Fig. 5C) (Fig. 6 ). Nuclear factor-B is a transcription factor that has been observed to regulate proteins such as cPLA 2 in inflammatory disease (33) . However, SN 50 (a NF-B inhibitor, 500 ng/ml) did not significantly prevent the effect of uric acid on [ 3 H]AA release by the PTCs. NF-B is bound to IB-␣. In stimulated cells, IB-␣ is phosphorylated and dissociates from NF-B, which enters the nucleus. We examined the effects of uric acid on expression level of NF-B and phospho IB-␣ by the primary PTC cultures. Figure 7A shows that following a 30-min incubation, uric acid increased the level of expression of NF-B p65, the active subunit of the NF-B complex, and the level of phospho IB-␣ with a concomitant decrease in IB-␣. The ability of nuclear NF-B/Rel to bind to an NF-B consensus oligonucleotide was examined by means of an EMSA. As shown in Fig. 7B , specific binding of nuclear NF-B to consensus oligonucleotides increased following uric acid treatment and was maximal after 60 min.
Involvement of NF-B in the uric acid-induced inhibition of
To further evaluate the involvement of NF-B in mediating the uric acid-induced inhibition of [ 3 H]thymidine incorporation, the effects of two NF-B inhibitors [PDTC (10 Ϫ5 M), an antioxidant, and SN 50, a nuclear translocation inhibitor] on the uric-acid induced inhibition of DNA synthesis were examined. Figure 8A shows that each of these NF-B blockers significantly reduced the inhibitory effect of uric acid on [ 3 H]thymidine incorporation. In addition, both PDTC and SN 50 individually blocked the uric acid-induced increase in NF-B p65 expression and NF-B binding activity (Fig. 8, B and C).
DISCUSSION
This study presents evidence indicating that 1) uric acid inhibits DNA synthesis by renal PTCs; and 2) the inhibitory effect of uric acid on DNA synthesis is mediated via at least two distinct signaling cascades involving, on one hand, PKC-MAPK-cPLA 2 and on the other hand NF-B. In human serum, hyperuricemia may occur because of decreased excretion (underexcretors) of uric acid, increased production (overproducers), or a combination of these two mechanisms (16) .
Previously, the effects of uric acid on renal proximal tubule cells have not been extensively studied. However, an understanding of the effects of uric acid on renal PTCs is important, as the renal proximal tubule is the major site for uric acid reabsorption and secretion in the kidney (16) . After initial filtration by the glomerulus, uric acid is subsequently reabsorbed by URAT1, an apical urate/anion exchange system in the renal proximal tubule (22) . Reabsorbed uric acid may also be secreted in the renal proximal tubule via basolateral organic anion transporters OAT1 and OAT3 (in exchange for dicarboxylate), as well as by apical voltage-driven organic anion efflux transporters (OATv1) and apical MRP4, a member of the ATP-binding cassette transporter family (22) .
The renal PTC culture system utilized in these studies has previously been shown to possess transport systems typical of the renal proximal tubule, including a high-affinity Na ϩ -glucose cotransport system typical of the straight portion of the renal proximal tubule, rather than the proximal convoluted tubule, which possesses a low-affinity, high-capacity Na ϩ -glucose cotransport system (40). Thus we cannot exclude the possibility that PTCs are also a model system for studying urate reabsorption, although our primary PTC culture system models are of urate-secreting renal PTCs. Although we have not directly measured intracellular urate accumulation or secretion in our studies, we have previously shown that our primary PTC cell culture system possesses a p-aminohippurate (PAH) transport system (45) . Indeed, such a PAH transport system (OAT1 and OAT3) has been proposed to be responsible for the secretion of uric acid as well as organic anions such as PAH (16) . Thus the results of our studies can be interpreted as indicating that under conditions of hyperuricemia, the transported uric acid inhibits the proliferation of urate-secreting renal PTCs. Uric acid reportedly stimulates rat vascular smooth muscle cell proliferation in vitro (28, 34) . The observed effects of uric acid on vascular smooth muscle cells cannot be explained by the activation of receptors for uric acid. Vascular smooth muscle cells are very likely responding to the effects of intracellular rather than extracellular uric acid. Vascular smooth muscle cells possess organic anion transporters responsible for urate uptake. In vascular smooth muscle cells, uric acid has been observed to activate two classes of MAP kinases (p44/42 MAPK and p38 MAPK), resulting in the activation of NF-B and ultimately an increase in cell proliferation (26) . The MAPK activation observed in vascular smooth muscle cells has been reported to result in the activation of NF-B, which results in increased production of growth factors (including PDGF) and increased cell growth.
Unlike the case with vascular smooth muscle cells, we have observed here that uric acid inhibits the proliferation of renal PTCs. Nevertheless, similarities in the mechanism of uric acid action were observed in the PTCs. As shown in Fig. 9 , uric acid activates PKC in PTCs, a necessary event for the activation of MAPK. However, unlike the case with vascular smooth muscle cells, in PTCs only p38 MAPK and SAPK/JNK are activated in response to uric acid, rather than p44/42 MAPK (which may explain the absence of a growth-stimulatory effect of uric acid in PTCs). NF-B activation is observed in the uric acid-treated PTCs, as was observed in the vascular smooth muscle cells. NF-B activation is essential for eliciting the inhibitory effect of uric acid on cell proliferation, rather than on growth. The activation of cPLA 2 was observed in PTCs in response to uric acid. Although PLA 2 activation was dependent on the activation of PKC and p38 MAPK by uric acid, our results indicated that NF-B was not involved. Thus our results indicate that the uric acid-mediated inhibition of PTC proliferation is dependent on two distinct pathways, one involving PKC, p38 MAPK, and cPLA 2 , and the other involving NF-B.
These differences in responsiveness may be due to differences between cell types (vascular smooth muscle cell vs. renal proximal tubule cell) and/or differences between species (rat vs. rabbit), rather than by differences in the concentrations of uric acid employed in the studies. The present report of an inhibitory effect of uric acid on renal PTC proliferation is consistent with the observed development of renal insufficiency in subjects with elevated uric acid (24) . In the present study, uric acid (at concentrations over 10 Ϫ4 M, or Ͼ2 mg/dl) were observed to inhibit thymidine incorporation into acidprecipitable material. This uric acid concentration (500 M) is within the range known to have deleterious physiological effects. Hyperuricemia is usually defined as Ͼ7 mg/dl (0.4 mM) in men and Ͼ6.5 mg/dl (Ͼ0.39 mM) in women (26) . Normal uric acid concentrations in humans are normally much higher than in other mammals due to the absence of uricase activity in humans and other primates. Indeed the uricase mutation has been proposed to have provided an evolutionary advantage because of the antioxidant action of uric acid (26) . However, this does not explain the observation that patients with higher uric acid levels with cardiovascular disease generally have worse outcomes (26) . Nevertheless, despite the lower levels of uric acid in other mammalian species, these other species have been successfully shown to model human hyperuricemia. An excellent example is the hyperuricemia, gout, and urate nephropathy observed in urate oxidase-deficient mice (44) .
To our knowledge, this is the first demonstration that uric acid can promote the translocation of PKC from the cytosol to the membrane fraction of renal PTCs. The role of PKC as a mediator of the inhibitory effect of uric acid on [ 3 H]thymidine incorporation was also indicated by our results with three PKC inhibitors, including bisindolylmaleimide I, staurosporine, and H-7. Each of these PKC inhibitors individually blocked the inhibitory effect of uric acid on [ 3 H]thymidine incorporation. Although both bisindolylmaleimide I and staurosporine can also inhibit cAMP-dependent protein kinase, at the concentrations of bisindolylmaleimide I and staurosporine utilized in this report (10 Ϫ7 and 10 Ϫ9 M, respectively), both of these inhibitors selectively inhibit PKC rather than PKA. Unlike the case with either bisindolylmaleimide I or staurosporine, H-7 is a relatively less-specific inhibitor. Nevertheless, the observation that PKC is translocated from the cytosol to the particulate fraction following treatment with uric acid, in combination with the observed effects of all three inhibitors, strongly suggests that PKC plays a role in mediating the inhibitory effect of uric acid on the proliferation of renal PTCs.
MAPKs also play critical roles in mediating the response of renal cells to stress and in promoting renal cell growth and survival (3, 15, 37) . Like most cells, three classes of MAPKs are expressed in renal PTCs, including extracellular-signal regulated kinases 1 and 2 (ERK 1/2), c-jun NH 2 -terminal kinase (JNK), and p38 MAPK (15) . However, little is known about the effect of uric acid on MAPKs in renal PTCs. The results of our investigations indicate that uric acid stimulates the phosphorylation and activation of both p38 MAPK and SAPK/JNK, whereas p44/42 MAPK was unaffected. In addition, our studies with the p38 MAPK inhibitor SB 203580, the SAPK/JNK inhibitor SP 600125, and the MEK1 inhibitor PD 98059 are also consistent with a role of p38 MAPK as well as SAPK/JNK in mediating the inhibitory effect of uric acid on [ 3 H]thymidine incorporation. At the concentration utilized in this report, SP200125 is a highly selective inhibitor of SAPK/ JNK as opposed to either p38 MAPK, p44/42 MAPK, or PKA (11) .
To our knowledge, our observation that uric acid causes the activation of JNK is novel and suggestive of a new mechanism that underlies the inhibitory effect of uric acid on the proliferation of PTCs. This result is consistent with a previous report that an effect of uric acid on the inhibition of JNK was associated with improved renal function following injury, and an accelerated rate of renal repair as normal renal function is once again obtained (9) .
Our results suggest that the activation of both PKC and p38 MAPK by uric acid is a contributing factor, which results in the phosphorylation of cPLA 2 and an increased release of AA from the PTCs, as observed in other experimental systems (4, 10, 23, 30) . The activation of PLA 2 has been associated with processes that lead to renal cell proliferation (1, 39) . However, our present results indicate that the activation of cPLA 2 is a part of the process that leads to the uric acid-induced inhibition of renal PTC proliferation.
Our observation of the activation of NF-B in response to uric acid is in agreement with previous reports with mononuclear phagocytes and smooth muscle cells (27, 31) . In these previous reports, NF-B activation by uric acid resulted in a stimulation of cell proliferation, unlike the case with our PTCs. However, the activation of NF-B is not necessarily associated with an increase in cell growth. Indeed, previous reports with cultured endometrial cells and monocytes show an association between NF-B activation and growth inhibition (2, 20) . Differences in response may be explained by cell type differences, as well as differences in the signaling pathways involved. We have obtained evidence indicating that cPLA 2 activation does not involve NF-B, although the PKC and p38 MAPK pathways are involved. However, we cannot exclude the possibility that PKC and p38 MAPK are also involved in the activation of NF-B in the PTCs, which also plays a role in the events which occur in response to hyperuricemia in renal PTCs. Further studies will be necessary to determine the relevance of these findings to the onset of renal disease. (43) 
